| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2405159 | Vaccine | 2009 | 6 Pages |
Abstract
The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis E virus (HEV). The safety and immunogenicity of the vaccine for humans was assessed in a randomized controlled phase II clinical trial. The study was conducted in an endemic area of southern China and consisted of a dose scheduling, involving 457 adults and a dose escalation component involving 155 high school students. The results showed that the vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jun Zhang, Chong-bo Liu, Rong-cheng Li, Yi-min Li, Ying-jie Zheng, Yan-ping Li, Dong Luo, Bai-bin Pan, Yi Nong, Sheng-Xiang Ge, Jun-hui Xiong, James Wai-kuo Shih, Mun-Hon Ng, Ning-shao Xia,